Johnson & Johnson (NYSE:JNJ) on Monday agreed to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company focused on therapies for serious eye diseases, for $2.2 billion upfront plus potential milestone payments.
Simultaneously, the healthcare company entered a separate development funding pact with Blackstone Life Sciences to finance the Phase 3 clinical advancement of Ollin’s investigational eye therapy.
Johnson & Johnson Reports Favorable Data For Bipolar Study
Targeting Major Causes Of Vision Loss
The acquisition adds OLN324 to JNJ’s therapeutic pipeline, an investigational bispecific antibody to target two critical pathways driving retinal diseases: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).
With high Ang2 potency and a small minibody protein format, OLN324 could help clinicians better control retinal fluid.
Clinical teams are developing OLN324 to treat serious eye conditions including wet age-related macular degeneration (AMD) and diabetic macular edema.
Together, these retinal conditions affect more than 40 million people worldwide and stand as leading causes of vision loss.
Financial Terms and Blackstone Funding Arrangement
Under the definitive acquisition agreement, the company will pay $2.2 billion upfront for Ollin Biosciences, while additional regulatory and commercial milestones could bring Ollin up to approximately $1.125 billion more.
Both companies expect the transaction to close before the end of 2026.
Contingent upon the acquisition closing, Blackstone Life Sciences will pay Johnson & Johnson $750 million across multiple years to fully fund Phase 3 development of OLN324.
In return, Blackstone becomes eligible to receive single-digit royalties, along with specific regulatory and sales milestone payments as the therapy progresses.
JNJ Price Action: Johnson & Johnson shares were up 0.34% at $286.70 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



